AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. (Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2019)